By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Endocyte, Inc. 

3000 Kent Avenue

West Lafayette  Indiana  47906  U.S.A.
Phone: 765-463-7175 Fax: 765-463-9271


Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

Endocyte Technologies Video


Key Statistics

Ownership: Public

Web Site: Endocyte
Symbol: ECYT


Company News
Endocyte (ECYT) Reports Third Quarter 2016 Financial Results 11/10/2016 1:54:39 PM
Endocyte (ECYT) Announces Third Quarter 2016 Earnings Conference Call 11/3/2016 11:07:39 AM
Endocyte (ECYT) Presents Data On Two Lead Clinical Programs At European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016 8:48:35 AM
Endocyte (ECYT) Announces Presentations At The European Society For Medical Oncology (ESMO) 9/30/2016 7:32:45 AM
Endocyte (ECYT) To Present At The 2016 Wedbush PacGrow Healthcare Conference 8/10/2016 12:29:27 PM
Endocyte (ECYT) Co-Founder Resigns Effective Immediately as CEO, New Leader Named 6/20/2016 8:17:01 AM
Endocyte, Inc. (ECYT) Reports Third Quarter 2015 Financial Results And Provides Update On Clinical Progress 11/4/2015 7:32:04 AM
Endocyte, Inc. (ECYT) Announces Third Quarter 2015 Earnings Conference Call 10/28/2015 10:10:25 AM
Endocyte, Inc. (ECYT) To Present Data On EC1456 At The European Cancer Congress 2015 9/22/2015 8:43:49 AM
Endocyte, Inc. (ECYT) Announces Final Overall Survival Results From Phase IIb TARGET Trial In Non-Small Cell Lung Cancer Patients 9/8/2015 7:56:36 AM